Comparative Pharmacology
Head-to-head clinical analysis: MS CONTIN versus RYZOLT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MS CONTIN versus RYZOLT.
MS CONTIN vs RYZOLT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mu-opioid receptor agonist; binds to mu-opioid receptors in the CNS, modulating pain perception and emotional response to pain.
RYZOLT is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane, increasing serotonin levels in the synaptic cleft.
Oral: 15-30 mg every 8-12 hours; adjust based on pain severity and prior opioid use. Extended-release tablets must be swallowed whole; do not crush or chew. For opioid-naïve patients, start at 15 mg every 12 hours.
10 mg orally once daily
None Documented
None Documented
Terminal elimination half-life: 11-13 hours (range 8-24 hours). In elderly or hepatic impairment, half-life may be prolonged; acute dosing half-life ~2-4 hours.
Terminal elimination half-life is 12–15 hours in healthy adults; extended to 22–28 hours in patients with severe hepatic impairment.
Renal: ~90% (mostly as morphine-3-glucuronide and morphine-6-glucuronide, with ~10% as unchanged morphine); Fecal: <10%
Primarily hepatic metabolism with renal excretion of metabolites; renal elimination of unchanged drug <5%; biliary excretion accounts for ~10% of total clearance.
Category C
Category C
Opioid Analgesic
Opioid Analgesic